Date: 2012-12-10
Type of information: R&D agreement
Compound: protein biomarkers
Company: Myriad Genetics (USA) Sanofi (France) Population Health Research Institute (PHRI) (USA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: diabetes
Details: Myriad Genetics has announced that Myriad RBM , a wholly owned subsidiary of Myriad Genetics , has entered into a research collaboration with Sanofi and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBM will perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the world\'s longest and largest randomized clinical trial in pre- and early diabetes. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI. As part of the agreement, Myriad RBM will analyze over 8,000 serum samples collected in the ORIGIN study using its DiscoveryMAP® 250+ quantitative immunoassay panel. Sanofi conceived of the application of Myriad RBM\'s technology to ORIGIN with a goal of identifying biomarker profiles that may optimize treatment and improve patient care.
Funded by Sanofi and directed and managed by PHRI, ORIGIN is a unique, six-year landmark cardiovascular (CV) outcomes trial, that evaluated Lantus® (insulin glargine) versus standard care in over 12,500 individuals at high CV risk with pre-diabetes or early type 2 diabetes mellitus. Spanning 40 countries worldwide, it was the world\'s longest and largest randomized clinical trial of its type in this population.
Financial terms: This collaboration could represent up to $10 million in companion diagnostic service revenue for Myriad over the next two fiscal years.
Latest news:
